Literature DB >> 19732779

Structural evaluation of potent NKT cell agonists: implications for design of novel stimulatory ligands.

André Schiefner1, Masakazu Fujio, Douglass Wu, Chi-Huey Wong, Ian A Wilson.   

Abstract

Natural killer T (NKT) cells are a subset of T cells that are activated by CD1d-glycolipid complexes through a semi-invariant alphabeta T cell receptor (NKT TCR). Upon activation, NKT cells secrete regulatory cytokines that are implicated in T helper cell responses. alpha-Galactosylceramide (alpha-GalCer) is a potent NKT cell agonist when presented by CD1d. Phenyl ring substitutions of the alpha-GalCer fatty acid moiety were recently found to be superior in eliciting regulatory cytokines. Crystal structures of four new mouse CD1d-lipid complexes (five structures), a new PBS-25 complex, and CD1d with an endogenous ligand, at 1.6-1.9 A resolution, reveal that the alpha-GalCer phenyl analogues impart minor structural differences to the A'-pocket, while the sphingosine and galactose moieties, important for NKT TCR recognition, remain virtually unchanged. The observed differences in cytokine-release profiles appear to be associated with increased stability of the CD1d-glycolipid complexes rather than increased affinity for the NKT TCR. Furthermore, comparison of mouse CD1d-glycolipid complexes in different crystallographic space groups reveals considerable conformational variation, particularly above the F'-pocket, the primary site of interaction with the NKT TCR. We propose that modifications of the sphingosine moiety or other substitutions that decrease alpha-GalCer flexibility would stabilize the F'-pocket. Such compounds might then increase CD1d affinity for the NKT TCR and further enhance the stimulatory and regulatory properties of alpha-GalCer derivatives.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19732779      PMCID: PMC2792987          DOI: 10.1016/j.jmb.2009.08.061

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  33 in total

1.  Four A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical.

Authors:  Y H Ding; B M Baker; D N Garboczi; W E Biddison; D C Wiley
Journal:  Immunity       Date:  1999-07       Impact factor: 31.745

Review 2.  Toward an understanding of NKT cell biology: progress and paradoxes.

Authors:  Mitchell Kronenberg
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

3.  Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activity.

Authors:  Masakazu Fujio; Douglass Wu; Raquel Garcia-Navarro; David D Ho; Moriya Tsuji; Chi-Huey Wong
Journal:  J Am Chem Soc       Date:  2006-07-19       Impact factor: 15.419

Review 4.  CD1 antigen presentation: how it works.

Authors:  Duarte C Barral; Michael B Brenner
Journal:  Nat Rev Immunol       Date:  2007-12       Impact factor: 53.106

Review 5.  Immunotherapeutic potential for ceramide-based activators of iNKT cells.

Authors:  Celia R Berkers; Huib Ovaa
Journal:  Trends Pharmacol Sci       Date:  2005-05       Impact factor: 14.819

6.  Design of natural killer T cell activators: structure and function of a microbial glycosphingolipid bound to mouse CD1d.

Authors:  Douglass Wu; Dirk M Zajonc; Masakazu Fujio; Barbara A Sullivan; Yuki Kinjo; Mitchell Kronenberg; Ian A Wilson; Chi-Huey Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

7.  Crystal structures of mouse CD1d-iGb3 complex and its cognate Valpha14 T cell receptor suggest a model for dual recognition of foreign and self glycolipids.

Authors:  Dirk M Zajonc; Paul B Savage; Albert Bendelac; Ian A Wilson; Luc Teyton
Journal:  J Mol Biol       Date:  2008-01-31       Impact factor: 5.469

8.  The T cell antigen receptor expressed by Valpha14i NKT cells has a unique mode of glycosphingolipid antigen recognition.

Authors:  Stéphane Sidobre; Kirsten J L Hammond; Lise Bénazet-Sidobre; Sergei D Maltsev; Stewart K Richardson; Rachel M Ndonye; Amy R Howell; Teruyuki Sakai; Gurdyal S Besra; Steven A Porcelli; Mitchell Kronenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-10       Impact factor: 11.205

9.  Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation.

Authors:  Jin S Im; Pooja Arora; Gabriel Bricard; Alberto Molano; Manjunatha M Venkataswamy; Ian Baine; Elliot S Jerud; Michael F Goldberg; Andres Baena; Karl O A Yu; Rachel M Ndonye; Amy R Howell; Weiming Yuan; Peter Cresswell; Young-Tae Chang; Petr A Illarionov; Gurdyal S Besra; Steven A Porcelli
Journal:  Immunity       Date:  2009-06-19       Impact factor: 31.745

10.  The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation.

Authors:  Corinna McCarthy; Dawn Shepherd; Sebastian Fleire; Victoria S Stronge; Michael Koch; Petr A Illarionov; Giovanna Bossi; Mariolina Salio; Galit Denkberg; Faye Reddington; Andrea Tarlton; B Gopal Reddy; Richard R Schmidt; Yoram Reiter; Gillian M Griffiths; P Anton van der Merwe; Gurdyal S Besra; E Yvonne Jones; Facundo D Batista; Vincenzo Cerundolo
Journal:  J Exp Med       Date:  2007-05-07       Impact factor: 14.307

View more
  23 in total

1.  Divergent synthetic approach to 6''-modified α-GalCer analogues.

Authors:  Nora Pauwels; Sandrine Aspeslagh; Gerd Vanhoenacker; Koen Sandra; Esther D Yu; Dirk M Zajonc; Dirk Elewaut; Bruno Linclau; Serge Van Calenbergh
Journal:  Org Biomol Chem       Date:  2011-11-01       Impact factor: 3.876

Review 2.  Small-angle scattering for structural biology--expanding the frontier while avoiding the pitfalls.

Authors:  David A Jacques; Jill Trewhella
Journal:  Protein Sci       Date:  2010-04       Impact factor: 6.725

3.  A molecular basis for the exquisite CD1d-restricted antigen specificity and functional responses of natural killer T cells.

Authors:  Kwok S Wun; Garth Cameron; Onisha Patel; Siew Siew Pang; Daniel G Pellicci; Lucy C Sullivan; Santosh Keshipeddy; Mary H Young; Adam P Uldrich; Meena S Thakur; Stewart K Richardson; Amy R Howell; Petr A Illarionov; Andrew G Brooks; Gurdyal S Besra; James McCluskey; Laurent Gapin; Steven A Porcelli; Dale I Godfrey; Jamie Rossjohn
Journal:  Immunity       Date:  2011-03-03       Impact factor: 31.745

Review 4.  Raising the roof: the preferential pharmacological stimulation of Th1 and th2 responses mediated by NKT cells.

Authors:  James E East; Andrew J Kennedy; Tonya J Webb
Journal:  Med Res Rev       Date:  2012-12-13       Impact factor: 12.944

Review 5.  Targeting the diverse immunological functions expressed by hepatic NKT cells.

Authors:  Caroline C Duwaerts; Stephen H Gregory
Journal:  Expert Opin Ther Targets       Date:  2011-05-13       Impact factor: 6.902

6.  Avidity of CD1d-ligand-receptor ternary complex contributes to T-helper 1 (Th1) polarization and anticancer efficacy.

Authors:  Tai-Na Wu; Kun-Hsien Lin; Ya-Jen Chang; Jing-Rong Huang; Jing-Yan Cheng; Alice L Yu; Chi-Huey Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-10       Impact factor: 11.205

7.  The Vα14 invariant natural killer T cell TCR forces microbial glycolipids and CD1d into a conserved binding mode.

Authors:  Yali Li; Enrico Girardi; Jing Wang; Esther Dawen Yu; Gavin F Painter; Mitchell Kronenberg; Dirk M Zajonc
Journal:  J Exp Med       Date:  2010-10-04       Impact factor: 14.307

Review 8.  Molecular basis of lipid antigen presentation by CD1d and recognition by natural killer T cells.

Authors:  Enrico Girardi; Dirk M Zajonc
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

Review 9.  The CD1 family: serving lipid antigens to T cells since the Mesozoic era.

Authors:  Dirk M Zajonc
Journal:  Immunogenetics       Date:  2016-07-02       Impact factor: 2.846

10.  Enhanced TCR footprint by a novel glycolipid increases NKT-dependent tumor protection.

Authors:  Sandrine Aspeslagh; Marek Nemčovič; Nora Pauwels; Koen Venken; Jing Wang; Serge Van Calenbergh; Dirk M Zajonc; Dirk Elewaut
Journal:  J Immunol       Date:  2013-08-19       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.